drugset / Trial / NCT00860522
JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia
Non-randomizedCrossoverOpen-labelTreatment
Summary
This is a Phase 1, open-label, dose escalation study of JVRS-100. The study will proceed in 2 stages to minimize the number of patients treated at doses substantially below the recommended phase 2 dose. In stage 1, an accelerated titration schema will be followed with one patient at each dose level. Stage 2 will commence after a dose limiting toxicity is observed in stage 1 or after the maximum dose for stage 1 is reached. Stage 2 will follow a modified Fibonacci schema with 3-6 subjects at each dose level until a recommended phase 2 dose is determined. The cohort will then be expanded to a maximum of 12 patients to more fully evaluate the recommended phase 2 dose.
Timeline
- Start
- 2009-03-01
- Primary completion
- 2014-10-31
- Completion
- 2017-02-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JVRS-100 | Unknown | 0.5 ug/kg | — |
| Subject | JVRS-100 | Unknown | 1 ug/kg | — |
| Subject | JVRS-100 | Unknown | 2 ug/kg | — |
| Subject | JVRS-100 | Unknown | 4 ug/kg | — |